Wenbin Kuang

Wenbin Kuang

Auto-generated profile, based on publicly available information

Wenbin Kuang

State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 210009 China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
DHDabao He
Dabao He
XYXiaoling Yang
Xiaoling Yang
WKWenbin Kuang
Wenbin Kuang
GHGuoqing Huang
Guoqing Huang
XLXiaohong Liu
Xiaohong Liu
YZyonggang zhang
yonggang zhang
Background: Triple negative breast cancer (TNBC), a special subtype of breast cancer, is characterized by high recurrence, mortality and few treatments. To date, the key factors contributing to TNBC progression have not been fully identified. In the current study, we found a TNBC-related circular RNA (circRNA), circ-PGAP3, and explored its biological function, clinical significance and potential mechanism of action. Materials and Methods: The functional assay was carried out using CCK-8, colony formation and Transwell invasion assays. RIP, RNA pull-down and luciferase reporter assays were used to test the correlation between circ-PGAP3, miR-330-3p and Myc. The animal model was employed to verify the function of circ-PGAP3 in vivo. Results: Circ-PGAP3 expression was significantly increased in TNBC tissues. High circ-PGAP3 was closely associated with large tumor size, lymph node metastasis, later TNM stage and dismal outcome. Through performing a series of in vitro and in vivo experiments, we found that circ-PGAP3 promoted TNBC cell growth and metastasis via sponging and inhibiting miR-330-3p, resulting in the upregulation of proto-oncogene Myc. Importantly, circ-PGAP3 expression was positively correlated with the Myc protein level but negatively correlated with miR-330-3p expression in TNBC tissues. Moreover, silencing of miR-330-3p or overexpression of Myc could effectively rescue the weakened malignant phenotype induced by circ-PGAP3 knockdown. Conclusion: Our results unveil the important driving role of circ-PGAP3 in TNBC development and progression, which provides a candidate therapeutic target for TNBC patients.

12 August 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DWDawei Wang
Dawei Wang
WWWenmu Wang
Wenmu Wang
MSMingge Song
Mingge Song
YXYishi Xie
Yishi Xie
WKWenbin Kuang
Wenbin Kuang
PYPeng Yang
Peng Yang

19 December 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
ZSZhongrui Shi
Zhongrui Shi
JLJiaxing Li
Jiaxing Li
JDJiayu Ding
Jiayu Ding
YZYiwen Zhang
Yiwen Zhang
WMWenjian Min
Wenjian Min
PYPeng Yang
Peng Yang
Recent extensive studies on the genomic and molecular profiles of acute myeloid leukemia (AML) have expanded the treatment options, including, a range of compounds represented by fms-like tyrosine kinase 3 and isocitrate dehydrogenase 1/2 inhibitors. However, despite this progress, further treatments for AML are still required. Adenosine deaminase acting on RNA 1 (ADAR1) has been shown to play an important oncogenic role in many cancers, but its involvement in AML progression remains underexplored. In this study, we demonstrated that ADAR1 was overexpressed in AML and served as a crucial oncogenic target. Loss of ADAR1 inhibited the Wnt signaling pathway, blocked AML cell proliferation, and induced apoptosis. Importantly, we demonstrate that ADAR1, as an RNA-binding protein, interacts with pri-miR-766 independently of its editing function, regulating the maturation of miR-766-3p and enhancing the expression of WNT5B. Genetic inhibition or use of the ADAR1 inhibitor ZYS-1 significantly suppressed AML cell growth both in vitro and in vivo. Overall, these results elucidated the tumorigenic mechanism of ADAR1 and validated it as a potential drug target in AML.

1 January 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KYKai Yuan
Kai Yuan
WKWenbin Kuang
Wenbin Kuang
WCWeijiao Chen
Weijiao Chen
MJMinghui Ji
Minghui Ji
WMWenjian Min
Wenjian Min
PYPeng Yang
Peng Yang

26 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
XWXiao Wang
Xiao Wang
WKWenbin Kuang
Wenbin Kuang
JDJiayu Ding
Jiayu Ding
JLJiaxing Li
Jiaxing Li
MJMinghui Ji
Minghui Ji
PYPeng Yang
Peng Yang
Pancreatic adenocarcinoma (PAAD) is a highly aggressive cancer. RNA-binding proteins (RBPs) regulate highly dynamic post-transcriptional processes and perform very important biological functions. Although over 1900 RBPs have been identified, most are considered markers of tumor progression, and further information on their general role in PAAD is not known. Here, we report a bioinformatics analysis that identified five hub RBPs and produced a high-value prognostic model based on The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets. Among these, the prognostic signature of the double-stranded RNA binding protein Staufen double-stranded RNA (STAU2) was identified. Firstly, we found that it is a highly expressed critical regulator of PAAD associated with poor clinical outcomes. Accordingly, the knockdown of STAU2 led to a profound decrease in PAAD cell growth, migration, and invasion and induced apoptosis of PAAD cells. Furthermore, through multiple omics analyses, we identified the key target genes of STAU2: Palladin cytoskeletal associated protein (PALLD), Heterogeneous nuclear ribonucleoprotein U (HNRNPU), SERPINE1 mRNA Binding Protein 1 (SERBP1), and DEAD-box polypeptide 3, X-Linked (DDX3X). Finally, we found that a high expression level of STAU2 not only helps PAAD evade the immune response but is also related to chemotherapy drug sensitivity, which implies that STAU2 could serve as a potential target for combinatorial therapy. These findings uncovered a novel role for STAU2 in PAAD aggression and resistance, suggesting that it probably represents a novel therapeutic and drug development target.

8 June 2020 in Human Cell
Verified
Journal Article
Closed access
PDF file
KWKuang Wenbin
Kuang Wenbin
LXLiu Xiaoqin
Liu Xiaoqin
DQDeng Qiuchan
Deng Qiuchan
ZXZheng Xinwen
Zheng Xinwen
XXXiao Xiaoqin
Xiao Xiaoqin
ZSZhu Shuangjiu
Zhu Shuangjiu